2013-12-23 14:28:17 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to ANI Pharmaceuticals Inc (ANIP) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering ANI Pharmaceuticals Inc (ANIP). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential ANI Pharmaceuticals Inc investor.
Report Summary: ANI Pharmaceuticals Inc is a low quality company with a positive outlook. ANI Pharmaceuticals Inc has weak business growth and is run by inefficient management. The trend in ANI Pharmaceuticals Inc fair value exchange rate against its closest rated-competitor, Transcept Pharmaceuticals Inc, has been depreciating over the past 2 weeks. When compared to its closest competitor, ANI Pharmaceuticals Inc shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of ANI Pharmaceuticals Inc for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.